Avior Wealth Management’s Outlook Therapeutics OTLK Stock Holding History

Avior Wealth Management’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1	Closed	-$11	–	3273
2024 Q1	$11	Buy	+1	New	+$8	﹤0.01%	3766

Other funds holding OTLK

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Altium Capital Management New York $42M AUM

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Avior Wealth Management's OTLK Position: Q2 2024 in Review

Avior Wealth Management sold out of Outlook Therapeutics (OTLK) in Q2 2024, closing a stake of 1 share — an estimated $11 sold.

Avior Wealth Management first reported a position in OTLK in Q1 2024 and held it in 1 quarter. The position peaked at $11 in Q1 2024. 64 funds tracked by Wall St. Rank hold OTLK as of Q2 2024.

Avior Wealth Management reported no remaining Outlook Therapeutics position as of Q2 2024 after selling out during the quarter.
Avior Wealth Management sold 1 Outlook Therapeutics share in Q2 2024, an estimated $11.
Avior Wealth Management first reported a position in Outlook Therapeutics in Q1 2024 and held it in 1 quarter.
Avior Wealth Management's Outlook Therapeutics position peaked at $11 in Q1 2024.
64 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.